Main Menu
Donate
Sign Up

Severely ill Patient Study

Study AIM

The aim of the Severely Ill Patient Study (SIPS), which started in 2015, was to conduct a comprehensive “Big Data” analysis on severely ill ME/CFS patients in order to begin an exploration to find the molecular basis of ME/CFS.

LEAD INVESTIGATORS
  • Ronald W. Davis, PhD
  • Wenzhong Xiao, PhD
Results / Reason for Discontinuation
  • This dataset will continue to be used for future analyses and has been made available to all interested researchers.
  • This study has produced two manuscripts.
  • A comprehensive look at the symptoms and clinical lab tests of severely ill patients and healthy controls:
  • An investigation of the pathogenesis of ME/CFS:

Hung, L-Y, et al. A Network Medicine Approach to Investigating ME/CFS Pathogenesis in Severely Ill Patients: A Pilot Study. (Preprint)

STUDY HYPOTHESIS AND DESCRIPTION

The hypothesis of the study was that molecular differences would show the strongest signal in severe cases of the illness when compared to healthy controls.

OBJECTIVES

Lab technician analyzing numerous medical graphs on a computer display

Using samples of saliva, blood, urine and feces, this big data study examines the following:

  • Genome
  • Gene expression on individual immune cell types
  • Metabolomics
  • Microbiome
  • Cell-free DNA sequencing and quantitation
  • Cytokines
  • Clinical tests

The value of a study of this magnitude is that it provides a foundation of invaluable information to generate hypotheses and to develop diagnostics and treatments. Further, all samples from one patient are taken at one point in time, enabling all measurements to reflect exactly what was happening in the body at that one time point. This allows the possibility for the discovery of biomarkers involving the relationships between different body systems that would not ordinarily be found.

Read the OMF funded research publication:

A Comprehensive Examination of Severely Ill ME/CFS Patients.

 

Other links you might be interested in:

Collaborative Research Center Stanford
The Ronald G. Tompkins ME/CFS Collaboration at the Harvard Affiliated Hospitals
Facebook Twitter Youtube Instagram Linkedin

OMF is a non-profit 501(c)(3) organization
(EIN# 26-4712664). All donations are tax-deductible to the extent allowed by law.

2024 YEAR END REPORT

Open Medicine Foundation®
29302 Laro Drive,  Agoura Hills, CA 91301 USA
Phone: 650-242-8669
info@omf.ngo

Contact Us

PRIVACY  |  COOKIE   |   CONSENT   |  MEDICAL & OTHER DISCLAIMERS

Copyright © 2025 Open Medicine Foundation. All Rights Reserved.

Consent management

Consent Preferences

Data Subject Access Request (DSAR) Form 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.


How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 
Give now from your
Donor-Advised Fund
 
Donate